Description

Actiq (Fentanyl Citrate) 400mcg OTFC Lozenges

Fentanyl pectin nasal spray offers an advantage in the time to onset of pain relief and
reduction in pain intensity of breakthrough pain compared with placebo and immediate
release morphine sulphate. Indirect comparison indicates broadly comparable efficacy to an
oral transmucosal fentanyl formulation and an existing fentanyl nasal spray.
Prescribers should be aware of the differing absorption and elimination characteristics of the
available nasal fentanyl preparations; doses are not interchangeable.https://www.familyfarepharmacy.net/

Actiq (Fentanyl Citrate) 400mcg OTFC Lozenges

Management of breakthrough pain (BTP) in adults who are already receiving maintenance
opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain
that occurs on a background of otherwise persistent pain.
Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral
morphine daily, at least 25microgram of transdermal fentanyl per hour, at least 30mg of
oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of
another opioid for a week or longer.https://www.medicines.org.uk/emc/landing?status=1#gref

400mcg OTFC Lozenges

Management of breakthrough pain (BTP) in adults who are already receiving maintenance
opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain
that occurs on a background of otherwise persistent pain.
Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral
morphine daily, at least 25microgram of transdermal fentanyl per hour, at least 30mg of
oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of
another opioid for a week or longer.
Dosing Information
Initially 100microgram intranasally and titrated to an effective dose that provides adequate
analgesia without causing undue (or intolerable) adverse reactions. Doses may be taken
every four hours to a maximum of four doses per day. Treatment should be initiated by and
remain under the supervision of a physician experienced in the management of opioid therapy
in cancer patients. Physicians should keep in mind the potential for abuse of fentanyl.
Product availability date
6 October 2010
Summary of evidence on comparative efficacy